Lipid nanoparticles for cyclosporine a administration: Development, characterization, and in vitro evaluation of their immunosuppression activity

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 6541-6553

  Guada, Melissa ^a,b   Sebastián, Victor ^c,d   Irusta, Silvia ^c,d   Feijoó, Esperanza ^a   Dios Viéitez, María del Carmen ^a   Blanco Prieto, María José ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b Instituto de Investigación Sanitaria de Navarra   (Spain)

^c UNIVERSITY OF ZARAGOZA   (Spain)

^d BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

Author keywords

Cyclosporine A; Immunosuppressive activity; Jurkat cells; Lipid nanoparticles; Oral administration; Stability

Indexed keywords

CYCLOSPORIN A; INTERLEUKIN 2; LIPID NANOPARTICLE; NANOPARTICLE; PHOSPHATIDYLCHOLINE; POLOXAMER; POLYSORBATE 80; TAUROCHOLIC ACID; UNCLASSIFIED DRUG; CYCLOSPORIN; EXCIPIENT; IMMUNOSUPPRESSIVE AGENT; LIPID; SURFACTANT;

ARTICLE; BIOCOMPATIBILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ACTIVITY; DRUG EFFICACY; DRUG FORMULATION; DRUG STABILITY; FREEZE DRYING; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; JURKAT CELL LINE; PARTICLE SIZE; PHYSICAL CHEMISTRY; SURFACE PROPERTY; TRANSMISSION ELECTRON MICROSCOPY; X RAY PHOTOELECTRON SPECTROSCOPY; X RAY POWDER DIFFRACTION; CHEMISTRY; MEDICINAL CHEMISTRY; ORAL DRUG ADMINISTRATION; SECRETION (PROCESS);

ADMINISTRATION, ORAL; CHEMISTRY, PHARMACEUTICAL; CYCLOSPORINE; EXCIPIENTS; FREEZE DRYING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; JURKAT CELLS; LIPIDS; NANOPARTICLES; PARTICLE SIZE; SURFACE-ACTIVE AGENTS;

EID: 84944903752     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S90849     Document Type: Article

References (36)

1. Survase SA, Kagliwal LD, Annapure US, Singhal RS. Cyclosporin A - a review on fermentative production, downstream processing and pharmacological applications. Biotechnol Adv. 2011;29(4):418-435.
2. Italia JL, Bhardwaj V, Ravi Kumar MN. Disease, destination, dose and delivery aspects of ciclosporin: the state of the art. Drug Discov Today. 2006;11(17-18):846-854.
3. Chiu YY, Higaki K, Neudeck BL, Barnett JL, Welage LS, Amidon GL. Human jejunal permeability of cyclosporin A: Influence of surfactants on P-glycoprotein efflux in Caco-2 cells. Pharm Res. 2003;20(5): 749-756.
4. Beauchesne PR, Chung NS, Wasan KM. Cyclosporine A: a review of current oral and intravenous delivery systems. Drug Dev Ind Pharm. 2007;33(3):211-220.
5. Schiff J, Cole E, Cantarovich M. Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin J Am Soc Nephrol. 2007;2(2): 374-384.
6. Lei Y, Lu Y, Qi J, et al. Solid self-nanoemulsifying cyclosporin A pellets prepared by fluid-bed coating: preparation, characterization and in vitro redispersibility. Int J Nanomedicine. 2011;6:795-805.
7. Dai W, Guo Y, Zhang H, Wang X, Zhang Q. Sylysia 350/Eudragit S100 solid nanomatrix as a promising system for oral delivery of cyclosporine A. Int J Pharm. 2015;478(2):718-725.
8. Mehnert W, Mäder K. Solid lipid nanoparticles: Production, characterization and applications. Adv Drug Deliv Rev. 2001;47(2-3):165-196.
9. Hauss DJ. Oral lipid-based formulations. Adv Drug Deliv Rev. 2007; 59(7):667-676.
10. Guada M, Imbuluzqueta E, Estella-Hermoso de Mendoza A, Lana H, Dios-Vieitez MC, Blanco-Prieto MJ. Ultra high performance liquid chromatography-tandem mass spectrometry method for cyclosporine a quantification in biological samples and lipid nanosystems. J Chromatogr B Analyt Technol Biomed Life Sci. 2013;927:164-172.
11. Müller RH, Runge S, Ravelli V, Mehnert W, Thünemann AF, Souto EB. Oral bioavailability of cyclosporine: Solid lipid nanoparticles (SLN) versus drug nanocrystals. Int J Pharm. 2006;317(1):82-89.
12. Urban-Morlan Z, Ganem-Rondero A, Melgoza-Contreras LM, Escobar-Chavez JJ, Nava-Arzaluz MG, Quintanar-Guerrero D. Preparation and characterization of solid lipid nanoparticles containing cyclosporine by the emulsification-diffusion method. Int J Nanomedicine. 2010;5:611-620.
13. Ankola D, Wadsworth R, Ravi Kumar M. Nanoparticulate delivery can improve peroral bioavailability of cyclosporine and match Neoral Cmax sparing the kidney from damage. J Biomed Nanotechnol. 2011;7(2): 300-307.
14. Guo J, Wu T, Ping Q, Chen Y, Shen J, Jiang G. Solubilization and pharmacokinetic behaviors of sodium cholate/lecithin-mixed micelles containing cyclosporine A. Drug Deliv. 2004;12(1):35-39.
15. Yu H, Xia D, Zhu Q, Zhu C, Chen D, Gan Y. Supersaturated polymeric micelles for oral cyclosporine A delivery. Eur J Pharm Biopharm. 2013; 85(3 Pt B):1325-1336.
16. Guan P, Lu Y, Qi J, et al. Enhanced oral bioavailability of cyclosporine A by liposomes containing a bile salt. Int J Nanomedicine. 2011;6: 965-974.
17. Chen D, Xia D, Li X, et al. Comparative study of Pluronic® F127-modified liposomes and chitosan-modified liposomes for mucus penetration and oral absorption of cyclosporine A in rats. Int J Pharm. 2013;449(1-2):1-9.
18. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161-177.
19. Estella-Hermoso de Mendoza A, Campanero MA, Lana H, et al. Complete inhibition of extranodal dissemination of lymphoma by edelfosine-loaded lipid nanoparticles. Nanomedicine (Lond). 2012;7(5): 679-690.
20. Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS Pharm Sci Tech. 2011; 12(1):62-76.
21. Westesen K, Siekmann B. Investigation of the gel formation of phospholipid-stabilized solid lipid nanoparticles. Int J Pharm. 1997; 151(1):35-45.
22. Westesen K, Siekmann B, Koch MH. Investigations on the physical state of lipid nanoparticles by synchrotron radiation X-ray diffraction. Int J Pharm. 1993;93(1-3):189-199.
23. Venkateswarlu V, Manjunath K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Release. 2004;95(3):627-638.
24. Wang K, Qi J, Weng T, et al. Enhancement of oral bioavailability of cyclosporine A: comparison of various nanoscale drug-delivery systems. Int J Nanomedicine. 2014;9:4991-4999.
25. Marangoni AG, Narine SS. Physical Properties of Lipids. United States: Marcel Dekker; 2002.
26. Fang J, Fang C, Liu C, Su Y. Lipid nanoparticles as vehicles for topical psoralen delivery: Solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur J Pharm Biopharm. 2008;70(2):633-640.
27. Ma Q, Zhang H, Zhao J, Gong Y. Fabrication of cell outer membrane mimetic polymer brush on polysulfone surface via RAFT technique. Appl Surf Sci. 2012;258(24):9711-9717.
28. Yeh SB, Chen CS, Chen WY, Huang CJ. Modification of silicone elastomer with zwitterionic silane for durable antifouling properties. Langmuir. 2014;30(38):11386-11393.
29. Kristensen EM, Nederberg F, Rensmo H, Bowden T, Hilborn J, Siegbahn H. Photoelectron spectroscopy studies of the functionalization of a silicon surface with a phosphorylcholine-terminated polymer grafted onto (3-aminopropyl) trimethoxysilane. Langmuir. 2006;22(23): 9651-9657.
30. Saad M, Gaiani C, Mullet M, Scher J, Cuq B. X-ray photoelectron spectroscopy for wheat powders: measurement of surface chemical composition. J Agric Food Chem. 2011;59(5):1527-1540.
31. Ren J, Eckert H. Quantification of Short and Medium Range Order in Mixed Network Former Glasses of the System GeO2-NaPO3: A Combined NMR and X-ray Photoelectron Spectroscopy Study. J Phys Chem C. 2012;116(23):12747-12763.
32. Schwarz C, Mehnert W. Freeze-drying of drug-free and drug-loaded solid lipid nanoparticles (SLN). Int J Pharm. 1997;157(2):171-179.
33. Cavalli R, Caputo O, Carlotti ME, Trotta M, Scarnecchia C, Gasco MR. Sterilization and freeze-drying of drug-free and drug-loaded solid lipid nanoparticles. Int J Pharm. 1997;148(1):47-54.
34. Kovačević AB, Müller RH, Savić SD, Vuleta GM, Keck CM. Solid lipid nanoparticles (SLN) stabilized with polyhydroxy surfactants: Preparation, characterization and physical stability investigation. Colloids Surf A Physicochem Eng Asp. 2014;444:15-25.
35. Hermans K, Van den Plas D, Everaert A, Weyenberg W, Ludwig A. Full factorial design, physicochemical characterisation and biological assessment of cyclosporine A loaded cationic nanoparticles. Eur J Pharm Biopharm. 2012;82(1):27-35.
36. Takebe G, Takagi T, Suzuki M, Hiramatsu M. Preparation of polymeric nanoparticles of cyclosporin A using infrared pulsed laser. Int J Pharm. 2011;414(1-2):244-250.